Evaluation of radiotherapy dose and survival outcomes for teenagers, and young adults with nasopharyngeal carcinoma in UK & Ireland
Our study suggests that paediatric protocols may adequately treat Epstein‑Barr virus‑positive TYA nasopharyngeal carcinoma.
Nasopharyngeal carcinoma (NPC) follows a bimodal distribution with a smaller incidence peak in teenagers and young adults (TYAs). In TYAs, an overwhelming proportion are associated with Epstein‑Barr virus (EBV). Given the rarity of TYA NPC and the lack of consensus regarding optimal management, we evaluated the variation in treatment patterns across the UK and Ireland, focusing on differences between paediatric (PP) and adult (AP) treatment protocols and associated survival outcomes.
This finding indicates that using lower‑dose paediatric radiotherapy regimens could provide effective disease control while potentially reducing long‑term toxicities in younger patients
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Efficacy and Toxicity of Triweekly Versus Weekly Cisplatin in Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
- Anti‑PD‑1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double‑blind phase 3 study
- Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma
- Nasopharyngeal Cancer
- Hierarchical dynamic model for risk‑stratified screening of nasopharyngeal carcinoma